Analysts Viewpoint Days-to-cover ratio for APLS surges to 6.88 due to rise in short interest Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its
Analysts Viewpoint Analysts review Apellis Pharmaceuticals Inc’s rating In a filing, Apellis Pharmaceuticals Inc revealed its Chief Executive Officer Francois Cedric unloaded Company’s shares for reported $0.4 million
Analysts Viewpoint Potential Price Increase for Apellis Pharmaceuticals Inc (APLS) After Recent Insider Activity In a filing, Apellis Pharmaceuticals Inc revealed its Chief Executive Officer Francois Cedric unloaded Company’s shares for reported $0.4 million